Eupraxia Pharmaceuticals Inc (TO:EPRX) — Market Cap & Net Worth
Market Cap & Net Worth: Eupraxia Pharmaceuticals Inc (EPRX)
Eupraxia Pharmaceuticals Inc (TO:EPRX) has a market capitalization of $319.49 Million (CA$441.65 Million) as of June 17, 2026. Listed on the TO stock exchange, this Canada-based company holds position #14645 globally and #431 in its home market, demonstrating a 4.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eupraxia Pharmaceuticals Inc's stock price CA$8.72 by its total outstanding shares 50648331 (50.65 Million). Review how much debt does Eupraxia Pharmaceuticals Inc carry to assess the company's total debt and financial obligations.
Eupraxia Pharmaceuticals Inc Market Cap History: 2021 to 2026
Eupraxia Pharmaceuticals Inc's market capitalization history from 2021 to 2026. Data shows growth from $89.76 Million to $319.49 Million (4.54% CAGR).
Eupraxia Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eupraxia Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EPRX by Market Capitalization
Companies near Eupraxia Pharmaceuticals Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Eupraxia Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Eupraxia Pharmaceuticals Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Eupraxia Pharmaceuticals Inc's market cap moved from $89.76 Million to $ 319.49 Million, with a yearly change of 4.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$319.49 Million | -15.50% |
| 2025 | CA$378.11 Million | +128.82% |
| 2024 | CA$165.24 Million | -16.01% |
| 2023 | CA$196.75 Million | +47.12% |
| 2022 | CA$133.73 Million | +48.98% |
| 2021 | CA$89.76 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Eupraxia Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $319.49 Million USD |
| MoneyControl | $319.49 Million USD |
| MarketWatch | $319.49 Million USD |
| marketcap.company | $319.49 Million USD |
| Reuters | $319.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more